Enliven Therapeutics, Inc.
ELVN
$36.97
$0.862.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M |
| Total Depreciation and Amortization | 14.00K | 46.00K | 62.00K | 81.00K | 74.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.76M | 12.56M | 6.96M | 7.88M | 6.84M |
| Change in Net Operating Assets | -3.43M | 1.22M | -157.00K | 313.00K | -2.50M |
| Cash from Operations | -19.29M | -15.84M | -13.28M | -17.06M | -24.13M |
| Capital Expenditure | -- | 0.00 | 1.00K | -139.00K | -20.00K |
| Sale of Property, Plant, and Equipment | -- | 213.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.53M | 12.17M | -4.06M | -183.45M | 1.45M |
| Cash from Investing | 42.53M | 12.38M | -4.06M | -183.59M | 1.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.05M | 721.00K | -- | 218.38M | 234.00K |
| Repurchase of Common Stock | -- | -- | -249.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -98.00K | -119.00K | -- | -- |
| Cash from Financing | 10.05M | 623.00K | -368.00K | 218.38M | 234.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.29M | -2.84M | -17.71M | 17.73M | -22.47M |